source
- Amgen seeks FDA hearing to keep rare kidney drug Tavneos amid safety concernsAmgen has asked the U.S. Food and Drug Administration for a hearing to argue against a proposed withdrawal of its rare‑disease drug Tavneos. The company submitted a data package containing real‑wo…
- Sanofi stops development of eczema drug amlitelimab after mixed trial resultsSanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent. The compan…